AAAAAA
Results: 1-25/28
Authors:
Bollens, R
Vanden Bossche, M
Roumeguere, T
Damoun, A
Ekane, S
Hoffmann, P
Zlotta, AR
Schulman, CC
Citation: R. Bollens et al., Extraperitoneal laparoscopic radical prostatectomy - Results after 50 cases, EUR UROL, 40(1), 2001, pp. 65-69
Authors:
Schulman, CC
Ekane, S
Zlotta, AR
Citation: Cc. Schulman et al., Nutrition and prostate cancer: Evidence or suspicion?, UROLOGY, 58(3), 2001, pp. 318-334
Authors:
Zlotta, AR
Citation: Ar. Zlotta, Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder - Editorial comment, J UROL, 166(5), 2001, pp. 1637-1637
Authors:
Zlotta, AR
Citation: Ar. Zlotta, Salvage intravesical therapy with interferon-alpha 2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancerin whom bacillus Calmette-Guerin alone previously failed - Editorial comments, J UROL, 166(4), 2001, pp. 1305-1305
Authors:
Zlotta, AR
Citation: Ar. Zlotta, Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: The Aarau experience - Editorial comment, J UROL, 166(3), 2001, pp. 855-855
Authors:
Schulman, CC
Altwein, JE
Zlotta, AR
Citation: Cc. Schulman et al., Treatment options after failure of local curative treatments in prostate cancer: a controversial issue, BJU INT, 86(9), 2000, pp. 1014-1022
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, Neoadjuvant and adjuvant hormone therapy for prostate cancer, WORLD J URO, 18(3), 2000, pp. 179-182
Authors:
Zlotta, AR
Citation: Ar. Zlotta, p53 immunohistochemistry as a prognostic marker in bladder cancer - Playground for urology scientists? Editorial comment, EUR UROL, 38(6), 2000, pp. 700-700
Authors:
Schulman, CC
Debruyne, FMJ
Forster, G
Selvaggi, FP
Zlotta, AR
Witjes, WPJ
Citation: Cc. Schulman et al., 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer, EUR UROL, 38(6), 2000, pp. 706-713
Authors:
Djavan, B
Zlotta, AR
Ekane, S
Remzi, M
Kramer, G
Roumeguere, T
Etemad, M
Wolfram, R
Schulman, CC
Marberger, M
Citation: B. Djavan et al., Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield, EUR UROL, 38(2), 2000, pp. 218-224
Authors:
Zlotta, AR
Citation: Ar. Zlotta, Two-year results of transurethral resection of the prostate versus four 'less invasive' treatment options - Editorial comment, EUR UROL, 37(6), 2000, pp. 701-701
Authors:
Zlotta, AR
Van Vooren, JP
Huygen, K
Drowart, A
Decock, M
Pirson, M
Jurion, F
Palfliet, K
Denis, O
Simon, J
Schulman, CC
Citation: Ar. Zlotta et al., What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?, EUR UROL, 37(4), 2000, pp. 470-477
Authors:
Zlotta, AR
Citation: Ar. Zlotta, Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer - Editorial comment, EUR UROL, 37(4), 2000, pp. 483-483
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, Biological response modifiers for the treatment of superficial bladder tumors, EUR UROL, 37, 2000, pp. 10-15
Authors:
Beerlage, HP
Thuroff, S
Madersbacher, S
Zlotta, AR
Aus, G
de Reijke, TM
de la Rosette, JJMCH
Citation: Hp. Beerlage et al., Current status of minimally invasive treatment options for localized prostate carcinoma, EUR UROL, 37(1), 2000, pp. 2-13
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, Biological markers in superficial bladder tumors and their prognostic significance, UROL CLIN N, 27(1), 2000, pp. 179
Authors:
Schulman, CC
Zlotta, AR
Denis, L
Schroder, FH
Sakr, WA
Citation: Cc. Schulman et al., Prevention of prostate cancer, SC J UROL N, 34, 2000, pp. 50-61
Authors:
Zlotta, AR
Van Vooren, JP
Denis, O
Drowart, A
Daffe, M
Lefevre, P
Schandene, L
De Cock, M
De Bruyn, J
Vandenbussche, P
Jurion, F
Palfliet, K
Simon, J
Schulman, CC
Content, J
Huygen, K
Citation: Ar. Zlotta et al., What are the immunologically active components of Bacille Calmette-Guerin in therapy of superficial bladder cancer?, INT J CANC, 87(6), 2000, pp. 844-852
Authors:
Zlotta, AR
Djavan, B
Damoun, M
Roumeguere, T
Petein, M
Entezari, K
Marberger, M
Schulman, CC
Citation: Ar. Zlotta et al., The importance of measuring the prostatic transition zone: an anatomical and radiological study, BJU INT, 84(6), 1999, pp. 661-666
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, Interstitial laser coagulation for the treatment of benign prostatic hyperplasia using local anaesthesia only, BJU INT, 83(3), 1999, pp. 341-342
Authors:
Zlotta, AR
Djavan, B
Ekane, S
Marberger, M
Schulman, CC
Citation: Ar. Zlotta et al., Is one set of transrectal sextant biopsies enough to rule out prostate cancer? A prospective evaluation, PROSTATE C, 2, 1999, pp. S36-S36
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, BPH and sexuality, EUR UROL, 36, 1999, pp. 107-112
Authors:
Zlotta, AR
Schulman, CC
Citation: Ar. Zlotta et Cc. Schulman, Clinical evolution of prostatic intraepithelial neoplasia, EUR UROL, 35(5-6), 1999, pp. 498-503
Authors:
de la Rosette, JJMCH
Zlotta, AR
Citation: Jjmch. De La Rosette et Ar. Zlotta, Future perspectives, EUR UROL, 35(2), 1999, pp. 173-176
Authors:
Djavan, B
Zlotta, AR
Remzi, M
Ghawidel, K
Bursa, B
Hruby, S
Wolfram, R
Schulman, CC
Marberger, M
Citation: B. Djavan et al., Total and transition zone prostate volume and age: How do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?, UROLOGY, 54(5), 1999, pp. 846-852